Sherif El-Refai a Ph.D. candidate at the University of Kentucky (UK), Sherif El-Refai focused his studies on clinical and experimental therapeutics. Sherif El-Refai also worked as an oncology pharmacist at UK Hospital’s Markey Cancer Center, where he published an article in early 2017 advocating for vaccination and screening to prevent cervical cancer.
Cervical malignancy/ cancer appears frequently when abnormal cells on the cervix grow out of control. The cervix is considered as the lowest part of the uterus which opens into a vagina. Cervical cancer can be dealt if identified at an early stage. It can be detected by a Pap test.
What causes cervical cancer?
Most cervical cancer is caused by a virus named as human papillomavirus or HPV. One can get HPV by having sexual contact with someone who has it. There are numerous varieties of the HPV virus. Not all varieties of HPV cause cervical cancer. A maximum number causes genital warts, whereas other types may not cause any symptoms.
Cervical cancer can frequently be avoided by having regular screenings to discover precancers and treat them. counteracting precancers implies controlling conceivable risk factors, such as:
Delaying first sexual intercourse until the late teens or older
Limiting the number of sex partners
Avoiding sexual intercourse with people who have had many partners
Avoiding sexual intercourse with people who are obviously infected with genital warts or show other symptoms
Screening is used to look for cancer or abnormalities that may become cancerous before you have any symptoms or signs. A researcher has created, and keep on developing, tests that can be utilized to screen a person for specific types of cancer before signs or manifestations show up. The general objective of malignancy screening is to:
Reduce the number of people who die from cancer, or completely eliminate deaths from cancer
Reduce the number of people who develop the cancer
Sherif El-Refai further states that cervical cancer often does not exhibit any symptoms until its advanced stages. According to Sherif El-Refai, getting vaccinated and following up with regular screenings is the best way to prevent cervical cancer.
With a doctor of pharmacy from the University of North Carolina at Chapel Hill, Sherif El-Refai is now working to earn a PhD in pharmaceutical sciences from the University of Kentucky. As a pharmacist Sherif El-Refai conducts lung cancer research and serves as an oncology pharmacist at the Black Lab, University of Kentucky’s Markey Cancer Center.
Lung cancer is the leading cause of cancer worldwide.The major two forms of lung cancer are nonsmall cell lung cancer (NSCLC=85%) of lung cancer and small-cell lung cancer (SCLC=15%). Despite recent advances in the management of resected lung cancer tumors and more effective treatments in the metastatic setting, the cure rate of lung cancer remains low. Successful molecular testing of lung cancer requires the identification and understanding of events that takes place during the multistep tumorigenic process of lung cancer. As with other solid tumors, lung cancer is the result of the accumulation of genetic and epigenetic alterations over a long course of exposure to a carcinogen.
Discovering new prognostic or predictive biomarkers or developing new detection tools for lung cancer is one of the major areas of transitional cancer research. However, given our current understanding of the multifactorial process of lung carcinogenesis and hetrogeneous nature of the disease, monitoring of one or a few genes is limited. A pangenomic analysis seems more efficient for deciphering the complexity of lung cancer. The prospect of identifying specific events in lung carcinogenesis is significantly brightened by the recent development of high-throughput gene expression analysis.
Sherif El-Refai further tried to understand Gene expression, a biological process at the cellular level involves the conversion of DNA information into molecules such as proteins. The process that allowed the cells to adjust to their surroundings by controlling when and how many proteins are to be produced. The gene expression includes two stages: transcription and translation. During transcription, DNA information is copied to produce messenger RNA, which carries the information to protein-producing ribosomes in the cell. Carrier molecules read this information during the translation stage, and ribosomes use it to form a new protein.
Sherif El-Refai is a dedicated academic who has recently earned an MBA from the University of Florida. Here, he focused on marketing, competitive strategy, and global management. While managing his studies, he also handled the role of the Case Competition Club, which he revived to offer students an opportunity to apply problem-solving skills to real business cases.
Prior to earning an MBA, Sherif El-Refai earned a doctor of pharmacy and a Bachelor of Science in pharmaceutical sciences from the University of North Carolina. (UNC) at Chapel Hill. He gained experience in the pharmaceutical field by doing comprehensive research and service work with organizations such as the Institute for Pharmacogenomics & Individualized Therapy, and the Center for Pharmacogenomics’ Department of Pharmacotherapy and Translational Research.
While working with the UNC Memorial Hospitals, he completed a comprehensive analysis if a specific treatment regimen for the company via Oncology, presented his findings to the company’s divisional board of directors, and induced the company to implement his recommended changes to the regimen.
Being an active member of the pharmaceutical industry, Sherif El-Refai has published research and performed presentations on a wide range of subjects, including Hypercalcemia of Malignancy. Besides being a renowned pharmacist,, he is also associated with the leading pharmacy organizations which adds five star to his profile. He also maintains memberships with the American Pharmacists Association, the American Society of Health-System Pharmacists, and the North Carolina Association of Pharmacists.
Sherif El-Refai is an experienced pharmacist who possess a Doctor of Pharmacy from the University of North Carolina Eshelman School of Pharmacy. He has held a number of research and volunteer positions throughout his academic career. He was even enrolled at the University of Florida Hough Graduate School of Business to complete his masters of business administration (MBA).
Sherif El-Refai a humanitarian and activist holds certification in pharmacy primarily-based immunization delivery; basic life support;and advance cardiac life support, anticoagulation, high blood pressure, lipids, and diabetes. He emphasize his education to a role as a pharmacist serving the needs of diverse patients by growing his clinical and industry knowledge. Since a long period of time he has been working to expand a well-rounded background in pharmacy.
Holding a doctorate of pharmacy, he has accumulated experience as both pharmacist and pharmaceutical researcher. He eventually gained huge amount of knowledge in business advancement from University of Florida, where he served as president of the Case Competition Club. He managed to balance his studies with his role as president of Case Competition Club, he revived to offer students an opportunity to apply problem-solving skills to commercial enterprise related cases.
As an active member of the pharmaceutical industry, Sherif El-Refai has published research and performed presentations on a wide range of subjects, including Hypercalcemia of Malignancy. He additionally maintains memberships with the American Pharmacists Association, the American Society of Health-System Pharmacists, and the North crolina Association of Pharmacists.
In pursuit of a PhD in pharmaceutical sciences at the University of Kentucky College of Pharmacy, Sherif El-Refai also serves as an oncology pharmacist at the university’s Markey Cancer Center. As part of the Black Lab at the College of Pharmacy, Sherif El-Refai researches the ways in which gene expression affects patient responses to cancer treatments.
Under the leadership of researcher J. Julius Zhu, associate professor of pharmacology, a research team at the University of Virginia School of Medicine has created a new technique that lets scientists more quickly assess gene mutations and their effect. The technique uses lentivirus, a form of retrovirus similar to the human immunodeficiency virus (HIV), which replaces normal genes with mutated versions.
The technology allows scientists to assess the effect of each mutation on the body. It is more time and cost efficient than currently available methods of studying gene mutation, and thus will be more accessible to the typical research laboratory. With this new technology, research that would have once taken 10 years will take only three months.
Dr. Zhu has suggested that this advancement will allow physicians to develop better customized treatments. By identifying the type and nature of a gene mutation, physicians may be able to suggest interventions that are likely to generate the proper level of gene activity.
A researcher at the University of Kentucky (UK) College of Pharmacy’s Black Lab, Sherif El-Refai studies how gene expression affects a person’s response to cancer therapy. Outside of his role as a researcher, Sherif El-Refai treats patients as an oncology pharmacist at the UK Markey Cancer Center.
In addition to offering cutting-edge cancer treatment, the Markey Cancer Center provides a wide range of support services to help patients cope with both physical and emotional pain. The center’s support services include nutrition planning, psycho-oncology services to treat anxiety and depression, art therapy, support groups, and palliative care at UK HealthCare.
The Markey Cancer Center also features a Jin Shin Jyutsu program, through which practitioners use gentle touch on targeted parts of the body to restore harmony to the body’s energy system. All of the center’s cancer patients receive five free sessions with a practitioner of this ancient healing art.
Also offering integrative medicine, or complementary medicine, the Markey Cancer Center combines traditional medicine with the use of mind-body practices and natural products. The center’s integrative medicine offerings range from acupuncture and massage therapy to hypnotherapy and relaxation techniques.
To learn more about the Markey Cancer Center and its cancer support services, visit UKHealthCare.uky.edu.
A graduate of the University of North Carolina Eshelman School of Pharmacy, Sherif El-Refai conducts research on lung cancer at the University of Kentucky College of Pharmacy. Sherif El-Refai concurrently serves as an oncology pharmacist at the University of Kentucky (UK) Markey Cancer Center, which has received recognition from the National Cancer Institute (NCI).
The UK Markey Cancer Center stands out as the only cancer center in the state of Kentucky and one of just 69 centers in the country to receive the coveted NCI designation. The honor recognizes cancer centers that have demonstrated excellence in laboratory and clinical research as well as behavioral and population-based studies.
NCI-designated cancer centers have access to exclusive clinical trials and new drugs and treatments. The designation also provides the Markey Cancer Center with an additional $2 million in funding per year and the opportunity to recruit some of the top medical students and faculty from around the world. The Markey Cancer Center also can collaborate on cancer research with other NCI-designated centers throughout the country.